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S U M M A R Y 
A double-blind clinical trial involving 120 patients with chronic schistosomia-
sis was carried out to compare the tolerability and efficacy of praziquantel and 
oxamniquine. The patients were randomly allocated into two groups. One was 
treated with praziquantel, 55 mg/kg of body weight CBWT), and the other one 
with oxamniquine, 15mg/kg bwt, administered in a single oral dose. The diag-
nosis and the parasitological follow-up was based on stool examinations by quan-
titative Kato-Katz method and on rectal biopsies. Side-effects — mainly dizziness, 
sleepness, abdominal distress, headache, nausea and diarrhea — were observed 
in 87% of the cases. Their incidence, intensity and duration were similar for both 
drugs but abdominal pain was significantly more frequent after praziquantel 
intake and severe dizziness was more commonly reported after oxamniquine. A 
significant increase of alanine-aminotransferase and y-glutamyltransferase was 
found with the latter drug and of total bilirubin with the former one. A 
total of 48 patients treated with praziquantel and 46 with oxamniquine com-
pleted with negative findings the required three post-treatment parasitological 
controls — three slides of each stool sample on the first, third and sixth month. 
The achieved cure rates were 79.2% and 84.8%, respectively, a difference without 
statistical significance. The non-cured cases showed a mean reduction in the 
number of eggs per gram of feces of 93.5% after praziquantel and of 84.1% after 
oxamniquine. This diference also was not significant. Five patients retreated 
with praziquantel were cured but only one out of three treated a second time 
with oxamniquine. These findings show that both drugs — despite their different 
chemical structures, pharmacological properties and mechanisms-of-action — in-
duce similar sid&effects as well as a comparable therapeutical efficacy, in agree-
ment with the results reported from analogous investigations. 
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I N T R O D U C T I O N 
Chemotherapy in a single-dose schedule with the treatment of schistosomiasis mansoni». The 
potent drugs represented a breakthrought in first one was hycanthone, mainly administered 
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by intramuscular route. Unfortunately, some 
cases of fatal toxic hepatitis *-6 and drug re­
sistance1^ were reported. 
With the appearance of oxamniquine, hy-
canthone was rapidly withdrawn and it is no 
longer available in Brazil. 
Over the last 10 years oxamniquine, a tetra 
hydroquinoline derivative, has been extensively 
used in our country, not only for individual 
treatment 2 8 but also as mass treatment 1 3. In­
teresting enough this drug showed a greater 
efficacy against the Brazilian strain of Schisto­
soma mansoni than against the African strain 1 8. 
Despite its good tolerability oxamniquine 
may cause unwanted side-effects such as: severe 
dizziness, mostly in fasting conditions 2 8; neu­
rological disturbances in animals 1 5 and in hu­
mans 1 8 and occasionaly seizures 2 « 2 5 . Moreover, 
elevation of serum activity of aminotransfera­
ses a few days after treatment has been report­
ed in some patients with schistosomiasis2 8. On 
the other hand, cases of resistance to oxamni­
quine have been published ] W , and finally its 
efficacy in humans was recently disputed in 
our country 8. 
These findings justified further investiga­
tions with new antischistosome agents. Prazi­
quantel, a heterocyclic pyrazino-isoquinoline 
compound, is a relatively new drug jointly de­
veloped by E. Merck — Darmstadt and Bayer 
AG — Leverkusen. I t was found to be parti­
cularly active against Schistosoma mansoni, S. 
haematobium and S. japonicum, the three main 
species pathogenic to man w ^ A * 2 . 
In order to compare the tolerability and 
efficacy of praziquantel and oxamniquine, this 
double-blind clinical trial was carried out. 
MATERIAL AND METHODS 
One hundred and twenty patients with 
chronic intestinal or hepato-intestinal forms of 
schistosomiasis were included in the trial. 
The selection of patients was based on age 
(older than 14 years), clinical form (hepatos-
plenic cases were not included) and worm 
burden established by three pre-treatment ex­
cretai egg counts according to Kato-Katz me­
thod 1 7 . Patients with associated acute and/or 
serious diseases and those who were pregnant 
or who have been treated within the previous 
6 months with any anti-schistosomal drug were 
excluded. 
After parasitological diagnosis, the 120 pa­
tients were randomly allocated into two groups 
having an equal number of cases. One received 
praziquantel 55 mg/kg bwt and the other group 
oxamniquine 15 mg/kg bwt. Both drugs were 
given in a single oral dose in accordance with 
a double-blind technique. 
Evaluation of symptoms and physical exa­
mination were performed on the same day and 
24 to 48 hours after the drug administration. 
Report of side-effects was attained through the 
spontaneous information of the patients. 
Blood was collected just before, 24 to 48 
hours and on the 7th. day after treatment. The 
following tests were accomplished: alanine-
aminotransferase ( A L T ) ; aspartate-aminotrans­
ferase ( A S T ) ; gammaglutamyl-transferase; and 
bilirubin. 
One patient was not included in the eva­
luation of tolerance and toxicity as he was. 
inadvertently treated with oxamniquine at the 
beginning of an assymptomatic viral hepatitis. 
The evolution was uneventful. 
The assessment of drug efficacy was based 
on three slides of each stool sample obtained 
prior to as well as one, three and six months 
after tretment 2 1. In 73 out of 77 patients with 
negative stool examinations up to the sixth 
month, 4 to 6 biopsies were taken from the 
valves of Houston during rectoscopy, always 
performed by the same investigator. 
Patients with less than three negative post-
treatment parasitological controls were not in­
cluded in the assessment of efficacy but all ca­
ses who eliminated viable eggs in any stool 
examination from the first month on after treat­
ment were considered as noncured; whenever 
feasible they were retreated with the same drug. 
The shortest period between both treatments 
was four months. 
For the statistical analysis u& of side-effects 
tables of contingency 2x3 were constructed, and 
the hypothesis of homogeneity between the two 
groups was tested by the Pearson's statistic. A 
"one-sample profile analysis" was utilized to 
evaluate the biochemical data; for comparing 
the therapeutical efficacy it was applied the 
chi-square test and the Mann-Whithney test to 
confront the reduction of eggs eliminated by 
the non-cured cases. Calculations were done by 
using the software Statistical Analysis System. 
RESULTS 
Clinical and parasitologlcal findings 
Sex, age, body-weight and egg counts from 
patients of the two groups were compared and 
no significant difference (p > 0.05) was found 
(Table I ) . All but three patients had more than 
100 S. mansoni eggs per gram of stools. 
Tolerabillty 
Side-effects following the administration 
•of praziquantel or oxamniquine were observed 
in 53 out of 60 patients (88.3%) and in 51 out 
of 59 (86.4%), respectively. The main complaints 
were dizziness, sleepness, abdominal pain or 
•disconfort, headache, nausea and diarrhea, (Ta­
ble I I ) . Abdominal pain was significantly more 
frequent (p < 0.001) after praziquantel intake. 
A severe degree of dizziness occurred in 13 out 
•of 59 cases (22.0%) after oxamniquine, and in 
5 out of 60 (8.3%) after praziquantel but this 
difference was not significant (p > 0.1), Most 
of the symptoms disappeared without additio­
nal medication within a few hours. 
Biochemical data 
Table I I I displays the data obtained before 
T 0 , two days ( T 2 ) and 7 days ( T 7 ) after chemo­
therapy. 
According to Wilks ( W ) and Fisher-Snede-
cor's ( F ) statistics, significant changes were 
observed with alanine-aminotransferase (p < 
0.05) and gammaglutamyltransferase (p < 0.01> 
after oxamniquine and with total bilirubin ( p < 
0.05) after praziquantel. In order to study the 
influence of time on these changes, the above-
mentioned liver function tests were further 
submitted to statistical analysis with the same 
methods. The results are shown in Table I V . 
A significant difference was observed between 
T 0 and T 7 and T 2 and T 7 for ALT and GGT 
after oxamniquine. For TB after praziquantel 
a significant difference was observed between 
T 2 and T 7 . 
Efficacy 
The parasitological follow-up examinations 
were completed in 94 patients. In the prazi­
quantel group 38 out of 48 (79.2%) were con­
sidered as cured; and in the oxamniquine 
group 39 out of 46 (84.8%). The difference was 
not statistically significant (p > 0.1). 
Rectal mucosa biopsies in 73 out of 77 
patients with three negative stool examinations 
did not show viable eggs. 
Considering the non-cured cases, except lor 
one who received oxamniquine, all of them had 
a marked decrease in the mean number of 
eggs eliminated per gram of feces. The average 
reduction after praziquantel was 93.5% and 
after oxamniquine 84.1% (Table V ) , a diffe­
rence without statistical significance (p > 0.1). 
Six out of the non-cured patients with 
praziquantel were treated again with the same 
drug. Five were followed up for six months and 
all were considered as cured. 
Retreatment with oxamniquine was carried 
out in four out of seven non-cured patients. 
Three completed the follow-up and only one 
was cured. A non-cured case was retreated once 
more but with praziquantel achieving parasito-
logical negativation. 
DISCUSSION 
These data show that praziquantel and 
oxamniquine produce similar side-effects, des­
pite their different chemical structures and 
pharmacological properties. Only abdominal 
pain was more frequently observed with pra­
ziquantel. Most of the post-chemotherapy symp­
toms, although being frequent, were of slight 
or moderate intensity and did not require symp­
tomatic medication. 
The serum enzymatic changes observed 
after oxamniquine intake deserve some com­
ments. I t is a well-known fact that following 
chemotherapy there is a worm shift from the 
terminal mesenteric veins to the liver. Thus, 
the significant elevation of alanine-aminotrans­
ferase and of gammaglutamyltransferase found 
with oxamniquine might be due to worm em­
bolization. As a matter of fact, an experimental 
study in infected and non-infected mice, un­
dertaken in our laboratories has demonstrated 
that oxamniquine leads to worm embolization, 
focal hepatic necrosis and a significant increase 
in serum aminotransferase activity in the in­
fected mice but no changes were seen in the 
control animals". The absence of serum énzi-
matic alterations ^ and the elevation of serum 
total bilirubin after praziquantel remain to be 
elucidated. , „ 
Parasitological negativation occurred in 38 
out of 48 patients (795%) under praziquantel 
administration and in 39 out of 46 (84.8% > 
under oxamniquine. Other investigators also 
have reported no significant difference between 
the efficacy of both drugs 3-13AZI. However, some 
•of them referred a lower 3 whereas others a 
higher 1 3 cure-rate. For children, higher doses 
of praziquantel, 70 mg/kg, as well as of oxam-
niquine, 20 mg/kg, are necessary for achieving 
a cure-rate of about 70% 1 2 A 
The results of retreatment are worth to 
be mentioned. Though the number of non-cured 
patients submitted twice to the same drug the-
rapy is rather small, there -was a tendency for 
the appearance of resistant cases to oxamniqui-
ne and apparently such occurrence does not 
influence the sensitivity of S. mansoni to pra-
ziquantel 1 1. 
RESUMO 
Estudo clínico duplo cego comparando 
praziquantel com oxamniquine 
Com objetivo de se compararem a tole-
rabilidade e eficácia do praziquantel e oxam-
niquine, procedeu-se a um estudo prospectivo 
duplo-cego envolvendo 120 pacientes com esquis-
tossomose intestinal ou hepatintestinal. 
Os pacientes foram randomizados em dois 
grupos. Um foi tratado com praziquantel, na 
dose de 55 mg/kg de peso, o outro com oxam-
niquine, 15 mg/kg de peso, sempre administra-
dos em dose única por via oral. O diagnóstico 
e seguimento parasitológicos basearam-se ho 
exame de fazes peio método de Kate Katz. Em 
73 de 77 casos negativos após tratamento, exe-
cutaram-se biópsias retais. 
Efeitos colaterais, principalmente tontura : 
sonolência, dores abdominais, cefaléia, náuseas 
e diarréia foram observados em 87% dos casos. 
Sua incidência, intensidade e duração foram se-
melhantes em ambos os grupos, mas a dor 
abdominal foi significativamente mais freqüen-
te após praziquantel, havendo maior tendência 
para tontura intensa após oxamniquine. Obser-
vou-se aumento significante de alamina-amino¬ 
transferase e gama-glutamiltransferase após 
oxamniquine e de bilirrubina total após prazi-
quantel. 
Um total de 48 pacientes tratados com pra-
ziquantel e 46 com oxamniquine completaram 
os exames de controle até o sexto mês. As 
percentages de cura foram de 79,2% e de 84,8% 
respectivamente, diferença não significativa. Os 
pacientes não curados mostraram redução mé-
dia do número de ovos de 93,5% e de 84,1%, 
diferença não significativa. Cinco pacientes re-
tratados com praziquantel curaram-se, mas so-
mente um de três retratados com oxamniquine. 
Estes resultados mostram, que ambas as 
drogas-apesar de diferentes propriedades far-
macológicas — provocam reações colaterais se-
melhantes e apresentam eficácia terapêutica 
comparável. 
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